Peripheral T-cell lymphoma

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Untreated

CHOEP-14 -> upfront autologous SCT

CHOEP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Etoposide, Prednisone

Regimen, d'Amore et al. 2012 (NLG-T-01)

Phase II

Etoposide is omitted for patients older than 60 years of age.

• Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
• Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
• Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
• Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
• Prednisone (Sterapred) 50 mg PO BID on days 1 to 5

14-day cycle x 6 cycles

If patients in PR or CR after three cycles, stem cells are mobilized off of cycles 5 and 6, followed by:

• BEAM or BEAC autologous stem cell transplant

References

1. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9. Epub 2012 Jul 30. link to original article contains verified protocol PubMed

CHOP

CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone

Synonyms: CHOP-21, ACOP, CAVP, COPA, VACP, VCAP

Structured Concept: C9549 (NCI-T), C0055598 (NCI-MT/UMLS)

Regimen, Simon et al. 2010 (GOELAMS LTP95)

Phase III

The evaluation arm, VIP-rABVD, was not superior and is not included here.

• Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
• Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
• Vincristine (Oncovin) 1.4 mg/m2 (maximum dose per cycle: 2 mg) IV once on day 1
• Prednisone (Sterapred) 100 mg/m2 PO once per day on days 1 to 5

21-day cycles x 8 cycles

Radiation therapy for initial bulky disease

"Initial bulky disease": patients with "diameter ≥5 cm"

• Radiation therapy, 40 Gy at 1.8 Gy/day to the involved field

References

1. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010 Oct;151(2):159-66. Epub 2010 Aug 25. link to original article contains verified protocol PubMed

CHOP -> upfront autologous SCT

CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone

Regimen, Reimer et al. 2004, 2009

Phase II

This study reports using CHOP but doesn't specify the doses; below is a fairly standard CHOP regimen:

• Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
• Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
• Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
• Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5

21-day cycle x 4 to 6 cycles

If CR obtained after 4 cycles or at least a PR after 6 cycles, patients were mobilized with G-CSF 4 to 6 weeks after, and then proceeded to receive either DexaBEAM or ESHAP induction followed by autologous stem cell transplant. Details are not available with regards to the conditioning regimens.

References

1. Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V, Weissinger F, Nerl C, Schmitz N, Müller-Hermelink HK, Wilhelm M. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5(4):304-11. PubMed
2. Update: Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink HK, Wilhelm M. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009 Jan 1;27(1):106-13. Epub 2008 Nov 24. link to original article PubMed
3. Meta-analysis: Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol. 2011;2011:623924. Epub 2011 Jun 16. link to original article PubMed

DD-CHOP

DD-CHOP: Denileukin, Diftitox, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone

Regimen, Foss et al. 2013 (CONCEPT)

Phase II

• Denileukin diftitox (Ontak) 18 mcg/kg IV over 60 minutes once per day on days 1 & 2
• Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 3
• Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 3
• Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 3
• Prednisone (Sterapred) 100 mg PO once per day on days 3 to 7

Supportive medications:

• Dexamethasone (Decadron) 4 to 8 mg IV/PO prior to Denileukin diftitox (Ontak)
• Acetaminophen (Tylenol) 650 mg PO prior to Denileukin diftitox (Ontak)
• Diphenhydramine (Benadryl) 25 mg IV prior to Denileukin diftitox (Ontak)
• Normal saline 250 to 500 cc before and after each Denileukin diftitox (Ontak) infusion
• Antiemetics "per institutional standard"
• G-CSF support beginning on day 4

21-day cycles x 6 to 8 cycles

References

1. Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013 Jul;54(7):1373-9. Epub 2013 Jan 29. link to original article contains verified protocol PubMed

Relapsed/refractory

Belinostat (Beleodaq)

Regimen, Pohlman et al. 2009; O'Connor et al. 2013 (BELIEF)

Phase II

• Belinostat (Beleodaq) 1000 mg/m2 IV over 30 minutes once per day on days 1 to 5

3-week cycles

References

1. Abstract: Pohlman, Brad, Advani, Ranjana, Duvic, Madeleine, Hymes, Kenneth B., Intragumtornchai, Tanin, Lekhakula, Arnuparp, Shpilberg, Ofer, Lerner, Adam, Ben-Yehuda, Dina, beylot-Barry, Marie, Hillen, Uwe, Fagerberg, Jan, Foss, Francine M. Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. ASH Annual Meeting Abstracts 2009 114: 920. link to abstract
2. Abstract: Owen A. O'Connor, Tamás Masszi, Kerry J. Savage, Lauren C. Pinter-Brown, Francine M. Foss, Leslie Popplewell, Amanda F. Cashen, Jeanette Doorduijn, Shanta Chawla, Poul Knoblauch, Pier Luigi Zinzani, Peter Brown, Georg Hess, Achiel Van Hoof, Steven M. Horwitz, Andrei R. Shustov. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. J Clin Oncol 31, 2013 (suppl; abstr 8507) link to abstract

Bendamustine (Treanda)

Regimen, Demaj et al. 2013 (BENTLY)

Phase II

• Bendamustine (Treanda) 120 mg/m2 IV once per day over 30 to 60 minutes on days 1 & 2

3-week cycles x 6 cycles

References

1. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. link to original article contains verified protocol PubMed

Brentuximab vedotin (Adcetris)

Regimen, Horwitz et al. 2014

Phase II

• Brentuximab vedotin (Adcetris) 1.8 mg/kg IV on day 1

3-week cycle until progression or unacceptable toxicity

References

1. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15;123(20):3095-100. Epub 2014 Mar 20. link to original article contains verified protocol PubMed

Lenalidomide (Revlimid)

Regimen, Morschhauser et al. 2013 (EXPECT)

Phase II

• Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21

28-day cycles, up to 2 years

References

1. Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. Epub 2013 May 31. link to original article contains protocol PubMed

Pralatrexate (Folotyn)

Example orders

• Example orders for Pralatrexate (Folotyn) in peripheral T-cell lymphoma

Regimen, O'Connor et al. 2011 (PROPEL)

Phase II

• Pralatrexate (Folotyn) 30 mg/m2 IV push over 3 to 5 minutes once per day on days 1, 8, 15, 22, 29, 36

Supportive medications:

• Cyanocobalamin (Vitamin B12) 1 mg IM once every 8 to 10 weeks
• Folic acid (Folate) 1 to 1.25 mg PO once per day
  • "Elevated methylmalonic acid (>200 nmol/L) and/or homocysteine (>10 μmol/L) at screening required initiation of Folic acid (Folate) and Cyanocobalamin (Vitamin B12) ≥ 10 days before the first dose of Pralatrexate (Folotyn)."

7-week cycles, given until progression of disease, unacceptable toxicity, or patient/physician preference

References

1. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. link to original article contains verified protocol PubMed

Romidepsin (Istodax)

Regimen, Coiffier et al. 2012

Phase II

• Romidepsin (Istodax) 14 mg/m2 IV over 4 hours once per day on days 1, 8, 15

28-day cycles, up to 6 cycles, with optional extension of treatment for patients with stable disease or response

References

1. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631-6. Epub 2012 Jan 23. link to original article contains verified protocol PubMed